[EN] FUSED 6,5 BICYCLIC RING SYSTEM P2 LIGANDS, AND METHODS FOR TREATING HIV [FR] LIGANDS P2 À SYSTÈME CYCLIQUE 6,5 BICYCLIQUE FUSIONNÉ, ET PROCÉDÉS DE TRAITEMENT D'UNE INFECTION PAR LE VIH
[EN] FUSED 6,5 BICYCLIC RING SYSTEM P2 LIGANDS, AND METHODS FOR TREATING HIV [FR] LIGANDS P2 À SYSTÈME CYCLIQUE 6,5 BICYCLIQUE FUSIONNÉ, ET PROCÉDÉS DE TRAITEMENT D'UNE INFECTION PAR LE VIH
[EN] METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS<br/>[FR] PROCÉDÉ ET COMPOSITIONS UTILISÉS POUR TRAITER LES INFECTIONS À VIH
申请人:PURDUE RESEARCH FOUNDATION
公开号:WO2008133734A4
公开(公告)日:2009-02-12
Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P<sub>2</sub> Ligands: Structure−Activity Studies and Biological Evaluation
作者:Arun K. Ghosh、Bruno D. Chapsal、Abigail Baldridge、Melinda P. Steffey、D. Eric Walters、Yasuhiro Koh、Masayuki Amano、Hiroaki Mitsuya
DOI:10.1021/jm1012787
日期:2011.1.27
The design, synthesis, and evaluation of a new series of hexahydrofuropyranol-derived HIV-1 protease inhibitors are described. We have designed a stereochemically defined hexahydrofuropyranol-derived urethane as the P2-ligand. The current ligand is designed based upon the X-ray structure of la-bound HIV-1 protease. The synthesis of (3aS,4S,7aR)-hexahydro-2H-furo[2,3-b]pyran-4-ol, (-)-7, was carried out in optically active form. Incorporation of this ligand provided inhibitor 35a, which has shown excellent enzyme inhibitory activity and antiviral potency. Our structure activity studies have indicated that the stereochemistry and the position of oxygens in the ligand are important to the observed potency of the inhibitor. Inhibitor 35a has maintained excellent potency against multidrug-resistant HIV-1 variants. An active site model of 35a was created based upon the X-ray structure of 1b-bound HIV-1 protease. The model offers molecular insights regarding ligand-binding site interactions of the hexahydrofuropyranol-derived novel P2-ligand.